Abiraterone Oral Tablet

Phase 3

ASTRAZENECA PLC (AZNCF)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

AZNCFPhase 3$290.6B

Abiraterone Oral Tablet Phase 3 Est. Readout

Abiraterone Oral Tablet• Metastatic Castration-resistant Prostate Cancer (mCRPC)750

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Metastatic Castration-resistant Prostate Cancer (mCRPC)

View Full Landscape

Drug Information

Target Indication

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clinical Trial

NCT03903835

Last updated: 9/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AZNCF

ASTRAZENECA PLC

Biotechnology•North America•NASDAQ

Related Pipeline

propranololPhase 3

Migraine Without Aura

Quetiapine SRPhase 3

Anxiety Disorders

Ceftaroline fosamilPhase 3

Infections

Erlotinib 150/100 mgPhase 3

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Ticagrelor orodispersible tabletsPhase 3

ST Elevation Myocardial Infarction

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts